Sjogren's syndrome
Not recruitingEvaluation of Dazodalibep Efficacy and Safety in Patients with Moderate-to-Severe Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
Evaluation of Dazodalibep Efficacy and Safety in Patients with Moderate-to-Severe Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
- Disease:Sjogren's syndrome
- Substances:Dazodalibep
Germany- Participants:18–64 years · 65+ years
- Substances:Dazodalibep
- Sponsor:Horizon Therapeutics Ireland Designated Activity Company












